Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q2

3341.TEDINET S100S9Q4
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥166.3bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥313.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥152.3bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥3.4bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥2.8bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥3.4bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥7.7bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥3.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥2.9bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥1.7bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.5bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.7bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥1.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥193.5bnat 2023-09-30Cons.Assets
Total assets¥185.3bnat 2023-03-31Cons.Assets
Total assets¥187.6bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥135.6bnat 2023-09-30Cons.Liabilities
Total liabilities¥128.8bnat 2023-03-31Cons.Liabilities
Net assets / equity¥57.9bnat 2023-09-30Cons.Net assets
Net assets / equity¥56.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥54.0bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥22.2bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥23.8bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥22.2bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥23.8bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥21.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥25.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥11.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥7.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥8.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥10.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥5.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥713m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥58.442023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥36.382023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥148.922022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥53.662022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥40.622022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio29.9%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio30.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio28.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 37
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥6.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥6.7bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥3.5bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥147.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥147.6bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥4.9bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥14m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥698m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥20.5bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥167m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥173.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥166.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥6.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥6.9bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥7.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥7.0bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥3.3bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥136.2bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥136.2bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥6.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥9m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥500m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥19.2bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥12.2bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥7.0bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥396m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥159.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥152.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥7.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥6.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Provision for directors bonusesPrior1YearInstant68000000JPY
Provision for directors bonusesCurrentQuarterInstant－JPY
Other clPrior1YearInstant8665000000JPY
Other clCurrentQuarterInstant9612000000JPY
Current liabilitiesPrior1YearInstant77050000000JPY
Current liabilitiesCurrentQuarterInstant86132000000JPY
Long term loans payablePrior1YearInstant44640000000JPY
Long term loans payableCurrentQuarterInstant41253000000JPY
Provision for directors retirement benefitsPrior1YearInstant79000000JPY
Provision for directors retirement benefitsCurrentQuarterInstant86000000JPY
Net defined benefit liabilityPrior1YearInstant2464000000JPY
Net defined benefit liabilityCurrentQuarterInstant2575000000JPY
Other nclPrior1YearInstant4579000000JPY
Other nclCurrentQuarterInstant5542000000JPY
Noncurrent liabilitiesPrior1YearInstant51763000000JPY
Noncurrent liabilitiesCurrentQuarterInstant49457000000JPY
LiabilitiesPrior1YearInstant128814000000JPY
LiabilitiesCurrentQuarterInstant135590000000JPY
Capital stockPrior1YearInstant3953000000JPY
Capital stockCurrentQuarterInstant3953000000JPY
Capital surplusPrior1YearInstant10926000000JPY
Capital surplusCurrentQuarterInstant10926000000JPY
Retained earningsPrior1YearInstant45216000000JPY
Retained earningsCurrentQuarterInstant46589000000JPY
Treasury stockPrior1YearInstant-3600000000JPY
Treasury stockCurrentQuarterInstant-3596000000JPY
Shareholders equityPrior1YearInstant56495000000JPY
Shareholders equityCurrentQuarterInstant57873000000JPY
Remeasurements of defined benefit plansPrior1YearInstant-12000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-10000000JPY
Valuation and translation adjustmentsPrior1YearInstant-12000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant-10000000JPY
Net assetsPrior1YearInstant56483000000JPY
Net assetsCurrentQuarterInstant57863000000JPY
Liabilities and net assetsPrior1YearInstant185297000000JPY
Liabilities and net assetsCurrentQuarterInstant193453000000JPY
Net salesPrior1YTDDuration152331000000JPY
Net salesCurrentYTDDuration166310000000JPY
Cost of salesPrior1YTDDuration125930000000JPY
Cost of salesCurrentYTDDuration138761000000JPY
Gross profitPrior1YTDDuration26400000000JPY
Gross profitCurrentYTDDuration27548000000JPY
Selling general and administrative expensesPrior1YTDDuration23587000000JPY
Selling general and administrative expensesCurrentYTDDuration24150000000JPY
Operating incomePrior1YTDDuration2813000000JPY
Operating incomeCurrentYTDDuration3397000000JPY
Commission fee noiPrior1YTDDuration19000000JPY
Commission fee noiCurrentYTDDuration23000000JPY
Rent income noiPrior1YTDDuration290000000JPY
Rent income noiCurrentYTDDuration306000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass